Subgroup analysis of trastuzumab deruxtecan reveals 'encoura

SABCS: Subgroup analysis of trastuzumab deruxtecan (T-DXd) shows ‘encouraging’ results in controlling stable brain metastases in HER2-positive

Related Keywords

Phoenix , Arizona , United States , Tennessee , San Antonio , Texas , Nashville , Switzerland , Jordan , Sara Hurvitz , Amgen Arqule Arvinas Astrazeneca , Astra Zeneca , Daiichi Sankyo , Roche Genentech Seattle , Hutchinson Medipharma Immunogen Immunomedics , Genentech Roche , Serono Fochon Fujifilm , Abbvie Acerta Pharma , Lilly Merck Mersana Novartis , Glaxosmithkline , Amgen , Jonsson Comprehensive Cancer Center , Bsc Of Health Interactions , Novartis , Phoenix Molecular Designs Ltd , Pfizer , Astrazeneca , Radius Health , Henryb Gonzalez Convention Center , National Comprehensive Cancer Network , Roche Ltd , Gilead Sciences , Drug Administration , Breast Cancer Clinical Research Program , Pieris Pharmaceuticals , Sarah Cannon Research Institute In Nashville , Comprehensive Cancer Center , San Antonio Breast Cancer Symposium , General Session , Antonio Breast Cancer Symposium , Comprehensive Cancer , Ownership Interest , Seattle Genetics , Trials Poster Session , Contracted Research , Cascadian Therapeutics , Phoenix Molecular Designs , Puma Biotechnology , Ideal Implant , Poster Discussion , Phoenix Molecular , Bonnie Jordan , Health Interactions , Erika Hamilton , Sarah Cannon Research Institute , Consulting Fees , Lilly Merck Mersana Novartis Pfizer , Genentech Seattle Genetics Silverback , Dana Farber Cancer Inst Deciphera , Merus Millennium , Convention Center ,